Sentence examples for months were randomized from inspiring English sources

In a double-blind, randomized, controlled design, 206 patients with documented cardiovascular disease and treated with hemodialysis for a minimum of 6 months were randomized to treatment with daily supplement of 1.7 g n-3 PUFA or placebo (olive oil) for 3 months.

Forty patients with refractory chronic tennis elbow pain (average duration of symptoms ~10 months) were randomized, 20 to each treatment.

Subjects receiving 3TC/ABC + PI + ritonavir (RTV) with HIV-1 RNA < 200 c/mL ≥3 months were randomized to continue 3TC/ABC or switch to FTC/TDF.

Eligible children aged 2 59 months were randomized to receive amoxicillin or benzyl penicillin and followed up for the primary outcome of treatment failure at 48hourss.

413 employed patients with back or neck pain referred to secondary care, and sick-listed between 4 weeks and 12 months, were randomized to a work-focused rehabilitation or control interventions.

Adults with type 2 diabetes inadequately controlled (A1C 7 11%) with maximally tolerated stable doses of metformin, sulfonylurea, or both for ≥3 months were randomized (1 1) to 1.8 mg liraglutide once daily or 10 μg exenatide twice daily.

Patients with ADPKD and kidney volume growth that can be documented within 6 months are randomized to treatment with sirolimus 2 mg/day for 18 months or standard treatment.

Mothers with major depressive disorder identified at 3 months postpartum were randomized into IH-CBT and ongoing home visitation (n = 47) or standard home visitation (SHV; n = 46) in which they received home visitation alone and could obtain treatment in the community.

If clinical remission (Disease Activity Score (DAS) <1.6) was not achieved within 4 months, patients were randomized into two treatment arms: either with a combination of nonbiologic DMARDs and low-dose prednisone or with MTX and the TNF-α inhibitor adalimumab (ADA).

Patients with active RA of at least six months duration were randomized into three cohorts to receive ISIS-CRPRx (100 mg, 200 mg or 400 mg) or placebo (3 active:1 placebo within each cohort) via subcutaneous (SC) injection on Days 1, 3, 5 and 8 and then once weekly for the next 11 weeks.

After a baseline of 6 months, every 3 months 3 hospitals were randomized to implement one or both interventions following a stepped wedge design.